Canadian drug developer Medicago’s plant-based Covid-19 vaccine candidate, enhanced by a GlaxoSmithKline treatment, was able to create a strong antibody antibody response in a mid-stage study, the two companies said on Tuesday.
The vaccine produced a neutralizing response that was about 10 times higher than in people recovering from Covid-19.
After two doses, the vaccine candidate induced robust immune responses in all the trial participants irrespective of age and no safety concerns or adverse events were reported, the companies said.
Medicago, which has Canada’s most advanced Covid-19 vaccine project under development, had in March started a late-stage study of the refrigerator-stable candidate in 30,000 participants in North America, Latin America and Europe.